Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the initiation of a Phase I clinical trial of the Company's lead drug candidate ME-143 in patients with refractory solid tumors...

Funded by the National Cancer Institute, investigators with the UCLA Department of Radiation Oncology at UCLA's Jonsson Comprehensive Cancer Center have discovered that the metabolic state of glioma stem cells, which instigate deadly glioblastomas, is considerably different from the metabolic state of brain cancer cells which the glioma stem cells created, a factor which as...